MA53541A - Dérivés hétéroaryles bicycliques - Google Patents

Dérivés hétéroaryles bicycliques

Info

Publication number
MA53541A
MA53541A MA053541A MA53541A MA53541A MA 53541 A MA53541 A MA 53541A MA 053541 A MA053541 A MA 053541A MA 53541 A MA53541 A MA 53541A MA 53541 A MA53541 A MA 53541A
Authority
MA
Morocco
Prior art keywords
bicyclic derivatives
heteroaryl bicyclic
heteroaryl
derivatives
bicyclic
Prior art date
Application number
MA053541A
Other languages
English (en)
Other versions
MA53541B1 (fr
Inventor
Jennifer Louise Carter
Hasane Ratni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA53541A publication Critical patent/MA53541A/fr
Publication of MA53541B1 publication Critical patent/MA53541B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA53541A 2018-09-03 2019-09-02 Dérivés hétéroaryles bicycliques MA53541B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18192219 2018-09-03
PCT/EP2019/073303 WO2020048904A1 (fr) 2018-09-03 2019-09-02 Dérivés hétéroaryles bicycliques

Publications (2)

Publication Number Publication Date
MA53541A true MA53541A (fr) 2021-12-08
MA53541B1 MA53541B1 (fr) 2024-02-29

Family

ID=63490310

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53541A MA53541B1 (fr) 2018-09-03 2019-09-02 Dérivés hétéroaryles bicycliques

Country Status (33)

Country Link
US (1) US12084461B2 (fr)
EP (1) EP3846903B1 (fr)
JP (1) JP7398435B2 (fr)
KR (1) KR102829709B1 (fr)
CN (1) CN112566696B (fr)
AR (1) AR116051A1 (fr)
AU (1) AU2019336492B2 (fr)
BR (1) BR112021002170A2 (fr)
CA (1) CA3107593A1 (fr)
CL (1) CL2021000486A1 (fr)
CO (1) CO2021002415A2 (fr)
CR (1) CR20210104A (fr)
DK (1) DK3846903T3 (fr)
ES (1) ES2966947T3 (fr)
FI (1) FI3846903T3 (fr)
HR (1) HRP20231663T1 (fr)
HU (1) HUE064554T2 (fr)
IL (1) IL281175B2 (fr)
LT (1) LT3846903T (fr)
MA (1) MA53541B1 (fr)
MX (1) MX2021002087A (fr)
MY (1) MY208133A (fr)
PE (1) PE20210860A1 (fr)
PH (1) PH12021550320A1 (fr)
PL (1) PL3846903T3 (fr)
PT (1) PT3846903T (fr)
RS (1) RS64950B1 (fr)
SG (1) SG11202102137SA (fr)
SI (1) SI3846903T1 (fr)
TW (1) TWI841592B (fr)
UA (1) UA128482C2 (fr)
WO (1) WO2020048904A1 (fr)
ZA (1) ZA202007831B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019412747B8 (en) 2018-12-27 2025-04-24 F. Hoffmann-La Roche Ag Process for the preparation exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994349A (en) 1997-10-27 1999-11-30 Howard University 3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives
CN1217918C (zh) 1998-04-01 2005-09-07 卡迪欧梅制药公司 氨基环己基醚化合物和其用途
WO2000047547A2 (fr) 1999-02-12 2000-08-17 Nortran Pharmaceuticals Inc. Composes d'amines cycloalkyles et utilisation de ceux-ci
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US6448246B1 (en) 1999-05-25 2002-09-10 Neurogen Corporation Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands
AU775102B2 (en) 1999-09-13 2004-07-15 David M. Swope Composition and method for decreasing neurologic symptomatology
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
WO2007032009A2 (fr) 2005-09-15 2007-03-22 Biomas Ltd. Utilisation de composes tellures pour le traitement du carcinome basocellulaire et/ou de la keratose actinique
CN101675045B (zh) 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 作为β-淀粉样蛋白调节剂的杂芳基苯胺
ATE543799T1 (de) 2007-10-19 2012-02-15 Janssen Pharmaceutica Nv Piperidinyl- und piperazinylmodulatoren von g- sekretase
JP5503663B2 (ja) 2008-11-13 2014-05-28 メルク・シャープ・アンド・ドーム・コーポレーション ガンマセクレターゼモジュレータ
RU2515976C2 (ru) 2009-02-26 2014-05-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие конденсированные гетероциклические соединения и их применение в качестве ингибиторов продукции бета-амилоида
WO2010138901A1 (fr) 2009-05-29 2010-12-02 Biogen Idec Ma Inc Composés contenant de l'acide carboxylique, leurs dérivés et procédés d'utilisation associés
US20120142672A1 (en) * 2009-07-13 2012-06-07 Tatsuki Koike Heterocyclic compound and use thereof
KR20120046327A (ko) 2009-09-04 2012-05-09 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 혼합된-금속-원자가 화합물에 기초한 멤리스터
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
CN103874702B (zh) * 2011-07-15 2015-12-09 杨森制药公司 作为γ分泌酶调节剂的经取代的吲哚衍生物
WO2014060112A1 (fr) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines utiles en tant qu'inhibiteurs de kinases
WO2017042114A1 (fr) 2015-09-09 2017-03-16 F. Hoffmann-La Roche Ag Dérivés de pipéridine pontés
EP3386978B1 (fr) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Dérivés de pipéridine pontés
CN109311878B (zh) 2016-06-27 2022-05-24 豪夫迈·罗氏有限公司 作为γ-分泌酶调节剂的三唑并吡啶类化合物
AR109829A1 (es) 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
EP3535266B1 (fr) 2016-11-01 2021-12-29 F. Hoffmann-La Roche AG Dérivés hétéroaryle bicycliques
US11319314B2 (en) 2016-11-08 2022-05-03 Hoffmann-La Roche Inc. Phenoxytriazoles
EP3554502A4 (fr) 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. Méthodes de traitement de la synaptopathie cochléaire
US11370802B2 (en) 2018-01-22 2022-06-28 Hoffmann-La Roche, Inc. Triazolo-azepine derivatives

Also Published As

Publication number Publication date
SI3846903T1 (sl) 2024-02-29
ES2966947T3 (es) 2024-04-25
JP2021535178A (ja) 2021-12-16
AR116051A1 (es) 2021-03-25
MY208133A (en) 2025-04-17
IL281175B2 (en) 2024-01-01
RS64950B1 (sr) 2024-01-31
EP3846903B1 (fr) 2023-10-25
PE20210860A1 (es) 2021-05-18
EP3846903A1 (fr) 2021-07-14
FI3846903T3 (fi) 2023-12-19
TWI841592B (zh) 2024-05-11
KR102829709B1 (ko) 2025-07-04
PH12021550320A1 (en) 2021-10-04
CR20210104A (es) 2021-04-19
DK3846903T3 (da) 2024-01-02
IL281175A (en) 2021-04-29
US12084461B2 (en) 2024-09-10
WO2020048904A1 (fr) 2020-03-12
TW202023649A (zh) 2020-07-01
MA53541B1 (fr) 2024-02-29
PL3846903T3 (pl) 2024-05-06
IL281175B1 (en) 2023-09-01
CN112566696A (zh) 2021-03-26
KR20210054515A (ko) 2021-05-13
BR112021002170A2 (pt) 2021-05-04
CN112566696B (zh) 2024-01-16
UA128482C2 (uk) 2024-07-24
SG11202102137SA (en) 2021-04-29
CO2021002415A2 (es) 2021-03-08
PT3846903T (pt) 2023-12-14
AU2019336492B2 (en) 2024-10-31
HRP20231663T1 (hr) 2024-03-15
AU2019336492A1 (en) 2021-01-07
ZA202007831B (en) 2026-03-25
CA3107593A1 (fr) 2020-03-12
MX2021002087A (es) 2021-04-28
HUE064554T2 (hu) 2024-03-28
JP7398435B2 (ja) 2023-12-14
US20210323980A1 (en) 2021-10-21
CL2021000486A1 (es) 2021-07-30
LT3846903T (lt) 2024-01-10

Similar Documents

Publication Publication Date Title
PT3958977T (pt) Derivados de camptotecina
DK3956033T3 (da) Bicykliske forbindelser
PL3897842T3 (pl) Pochodne bicykliczne
DK3728252T3 (da) 4-azaindolforbindelser
PT3687999T (pt) Derivados de rapamicina
LT3830085T (lt) Deuterinti lanifibranoro dariniai
MA41898A (fr) Dérivés de quinazolinone bicyclique
EP3457851A4 (fr) Dérivés de sobétirome
EP3654987A4 (fr) Utilisation de dérivés aminoalkylbenzothiazépine
PL4013751T3 (pl) Pochodne 2-hydroksycykloalkano-1-karbamoilu
HUE062157T2 (hu) Tumorellenes vegyületek
DK3768669T3 (da) Piperazinazaspiroderivater
PL3898637T3 (pl) Pochodne rapamycyny
EP4077334C0 (fr) Dérivés furoindazole
EP4021904C0 (fr) Dérivés d'alpha-d-galactopyranoside
EP3885347A4 (fr) Dérivé de dihydropyrrolopyrazole
EP3884940A4 (fr) Nouveau dérivé d'imidazole
EP3617195A4 (fr) Nouveaux dérivés de tétrahydronaphtyle urée
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
EP3554637A4 (fr) Dérivés de spiropipéridine
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
PT3796975T (pt) Derivados de sulfonilaminobenzamida
EP3472151A4 (fr) Dérivés de prolinamide carbocycliques
EP3400220A4 (fr) Dérivés de pyrazole
MA56504A (fr) Dérivés de pyridin-3-yle